XML 23 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenue:        
Precision oncology testing $ 166,518 $ 125,244 $ 322,747 $ 238,637
Development services and other 10,717 11,906 22,979 27,227
Total revenue 177,235 137,150 345,726 265,864
Costs and operating expenses:        
Cost of precision oncology testing 65,715 49,357 125,021 94,463
Cost of development services and other 6,706 4,491 12,696 12,458
Research and development expense 83,102 90,359 166,904 183,487
Sales and marketing expense 81,867 71,043 162,292 147,166
General and administrative expense 40,463 41,516 79,114 81,961
Total costs and operating expenses 277,853 256,766 546,027 519,535
Loss from operations (100,618) (119,616) (200,301) (253,671)
Interest income 13,913 6,727 28,781 9,787
Interest expense (645) (645) (1,290) (1,289)
Other income (expense), net (15,145) 41,259 (44,265) 39,605
Loss before provision for income taxes (102,495) (72,275) (217,075) (205,568)
Provision for income taxes 133 496 538 736
Net loss $ (102,628) $ (72,771) $ (217,613) $ (206,304)
Net loss per share, basic (in usd per share) $ (0.84) $ (0.67) $ (1.78) $ (1.95)
Net loss per share, diluted (in usd per share) $ (0.84) $ (0.67) $ (1.78) $ (1.95)
Weighted-average shares used in computing net loss per share, basic (in shares) 122,447 108,808 122,080 105,752
Weighted-average shares used in computing net loss per share, diluted (in shares) 122,447 108,808 122,080 105,752